Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2022 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
February 09, 2022 16:05 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
February 04, 2022 16:05 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
January 24, 2022 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces Appointment of Charlotte Jones-Burton, M.D., M.S. as Senior Vice President of Product Development and Strategy

SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
January 04, 2022 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
December 14, 2021 08:15 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Receives Orphan Drug Designation from European Commission for Atrasentan for Treatment of Primary IgA Nephropathy

Enrollment ongoing in atrasentan pivotal phase 3 ALIGN study in IgAN and phase 2 AFFINITY study in proteinuric glomerular diseasesChinook expects to present data from the IgAN patient cohort of the...
November 30, 2021 08:00 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China

50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners ChinaExpands global reach and execution for Chinook’s atrasentan and BION-1301 programs...
November 17, 2021 16:05 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics to Present at Upcoming Investor Conferences

SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
November 15, 2021 16:05 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces Closing of $183.5 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the closing of its upsized underwritten public offering of 9,538,572 shares of its common stock...
November 09, 2021 20:36 ET | Source: Chinook Therapeutics, Inc.

Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right